Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
190 results about "Cardiac dysfunction" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cardiac dysfunction is a frequent manifestation of Duchenne muscular dystrophy (DMD) and a common cause of death for individuals with this condition.
Implantable medical device for treating cardiac mechanical dysfunction by electrical stimulation
InactiveUS20040049235A1Increase the number ofHigh detection specificityHeart defibrillatorsHeart stimulatorsCardiac dysfunctionElectrical stimulations
The above-described methods and apparatus are believed to be of particular benefit for patients suffering heart failure including cardiac dysfunction, chronic HF, and the like and all variants as described herein and including those known to those of skill in the art to which the invention is directed. It will understood that the present invention offers the possibility of monitoring and therapy of a wide variety of acute and chronic cardiac dysfunctions. The current invention provides systems and methods for delivering therapy for cardiac hemodynamic dysfunction.
Owner:MEDTRONIC INC
Implantable medical device for treating cardiac mechanical dysfunction by electrical stimulation
InactiveUS7096064B2Improve toleranceExtension of timeHeart defibrillatorsHeart stimulatorsCardiac dysfunctionElectrical stimulations
The disclosure provides methods and apparatus of particular benefit for patients suffering heart failure including cardiac dysfunction, chronic HF, and the like and all variants thereof. According to the disclosure monitoring and therapy delivery for a wide variety of acute and chronic cardiac dysfunctions are described and depicted. Various forms of paired or coupled pacing therapy delivery provided alone or in combination with neurostimulation therapy delivered by both implantable and external apparatus, including defibrillation therapy are also provided herein.
Owner:MEDTRONIC INC
Detection of apex motion for monitoring cardiac dysfunction
InactiveUS20070032749A1Sensitive, immediate and accurateEarly diagnosisElectrotherapyPerson identificationCardiac dysfunctionMotion sensors
Systems, devices and methods for detecting and monitoring cardiac dysfunction. The devices include motion sensors for detecting signals representative of the total movement of the heart, and of the apex of the heart in particular.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Non-invasive method and apparatus for cardiac pacemaker pacing parameter optimization and monitoring of cardiac dysfunction
InactiveUS20050043767A1Uniform peak amplitudeEasy to detectHeart stimulatorsCardiac dysfunctionAmplitude response
A plethysmogram signal is sensed from a patient and provided to a programmer device for monitoring the condition of the patient and for optimizing pacing parameters of a cardiac device implanted in the patient. The programmer device analyzes the plethysmogram signal for cardiac performance associated with different pacing parameters. The cardiac performance is indicated by, for example, a pulse amplitude response, a degree of pulsus alternans, or irregularity in the pressure pulses detected in an atrial fibrillation patient. The pacing parameters resulting in the best cardiac performance are selected as the optimum pacing parameters. In one embodiment, the programmer device monitors a Valsalva maneuver performed by a patient. Optimum pacing parameters are derived by analysis of the plethysmogram signals obtained during performance of the Valsalva maneuver while the patient is paced using different pacing parameters.
Owner:CARDIAC PACEMAKERS INC
Antisense compositions targeted to beta1-adrenoceptor-specific mRNA and methods of use
InactiveUS6489307B1Reduce inhibitionInhibit and reduce expressionBiocideOrganic active ingredientsEccentric hypertrophyMammal
Disclosed are antisense oligonucleotide, polynucleotide, and peptide nucleic acid compounds that specifically bind to mammalian mRNA encoding a beta1-adrenoceptor polypeptide and that are useful in the control and / or treatment of cardiac dysfunction, hypertension, hypertrophy, myocardial ischemia, and other cardiovascular diseases in an affected mammal, and preferably, in a human subject. The antisense compounds disclosed herein, and pharmaceutical formulations thereof, provide sustained control of beta1-adrenoceptor expression over prolonged periods, and achieve therapeutic effects from as little as a single dose. Administration of these antisense compositions to approved animal models resulted in a decrease in blood pressure, but no significant change in heart rate. Use of such antisense compositions in the reduction of beta1-adrenoceptor polypeptides in a host cell expressing beta1-adrenoceptor-specific mRNA, and in the preparation of medicaments for treating human and animal diseases, and in particular, hypertension and other cardiac dysfunction is also disclosed.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Non-invasive method and apparatus for cardiac pacemaker pacing parameter optimization and monitoring of cardiac dysfunction
Owner:CARDIAC PACEMAKERS INC
Soluble Guanylate Cyclase Activators
This inventions relates to compounds having the structure Formula Iand pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.
Owner:MERCK SHARP & DOHME CORP
Soluble guanylate cyclase activators
A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.
Owner:MERCK SHARP & DOHME LLC
Systems, Methods and Apparatus for Treating Cardiac Dysfunction with Neurostimulation
InactiveUS20090318986A1Lower blood pressureLow pulmonary vascular resistanceHeart defibrillatorsHeart stimulatorsPeripheral neuronTherapeutic treatment
Methods, systems, and apparatus for the treatment of heart failure (both systolic and diastolic), hypertension, and arrhythmia in patients by stimulating one or more nerves, particularly peripheral nerves, using neurostimulation are described. The therapeutic treatment is accomplished by applying electrical signals to at least one or more nerves using cutaneous, subcutaneous, implantable, or catheter-based neurostimulation assemblies, alone or in combination with one or more additional therapy or stimulation devices associated with the patient's heart, and / or with one or more therapeutic drug infusions or therapies, such as immune modulation therapy (IMT).
Owner:THE METHODIST HOSPITAL RES INST
Soluble guanylate cyclase activators
The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
This inventions relates to compounds having the structure Formula Iand pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Cardiac pacing modality having improved blanking, timing, and therapy delivery methods for extra-systolic stimulation pacing therapy
InactiveUS20050090872A1Enhanced functional stateReduce their roleHeart stimulatorsCardiac dysfunctionSystole
The present invention relates to the secure delivery of an extra-systolic stimulation (ESS) therapy to treat cardiac dysfunction that employs atrial and / or ventricular extra-systoles via pacing-like stimulation of the heart. These extra-systoles must be timed correctly to achieve beneficial effects on myocardial mechanics (benefit) while maintaining an extremely low level of risk of arrhythmia induction and excellent ICD-like arrhythmia sensing and detection (security). Further experience with ESS has led to improved implementation methods that depend on better blanking, ESS stimulation timing (of an “extra-systolic interval” or ESI), and ESS therapy delivery options and guidance. These methods may be employed individually or in combinations in an external or implantable ESS therapy delivery device.
Owner:MEDTRONIC INC
Secure and efficacious therapy delivery for an extra-systolic stimulation pacing engine
ActiveUS20050101998A1Good curative effectEfficient productionHeart defibrillatorsHeart stimulatorsCardiac dysfunctionSystole
An extra-systolic stimulation (ESS) therapy addresses cardiac dysfunction including heart failure. ESS therapy employs atrial and / or ventricular extra-systoles via pacing-level stimulation to a heart. These extra-systoles must be timed correctly to achieve beneficial effects on myocardial mechanics (efficacy) while maintaining an extremely low level of risk of arrhythmia induction and excellent ICD-like arrhythmia sensing and detection (security). The present invention relates to therapy delivery guidance and options for improved ESS therapy delivery. These methods may be employed individually or in combinations in an external or implantable ESS therapy delivery device.
Owner:MEDTRONIC INC
Detection of apex motion for monitoring cardiac dysfunction
InactiveUS7445605B2Sensitive, immediate and accurateEarly diagnosisElectrotherapyPerson identificationCardiac dysfunctionMotion sensors
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Treatment of cardiac conditions
InactiveUS20130157953A1Useful in therapyIncrease ratingsPeptide/protein ingredientsMetabolism disorderEnergy balancingCardiac dysfunction
The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.
Owner:ZEALAND PHARM AS
Drug-eluting coated on surface of sacculus catheter air bag for alleviating vascular restenosis
The invention relates to a medical coating layer coated on the gasbag surface of a balloon pipe which can release the narrowing of blood vessel and reduce free radical damage after operation, belonging to the field of the medical instruments, which comprises 1% to 99% of medicine and 1% to 99% of medical carrier, wherein the medical comprises a single oxidation resisting medicine, or a mixture of a plurality of oxidation resisting medicines, or a mixture of a single or a plurality of oxidation resisting medicines with blood vessel narrowing resisting medicines; the medicines are evenly coated on the surface of the gasbag all together or layer by layer. The medical coating layer coated on the gasbag surface of a balloon pipe has the advantages that through local medication the damage to human cells and organizations after blood transfusion due to myocardial ischemia can be effectively released and reduced and the cardiac dysfunction can be finally cured.
Owner:天津百畅医疗器械有限公司
Secure and efficacious therapy delivery for an extra-systolic stimulation pacing engine
ActiveUS7233824B2Good curative effectEfficient productionHeart defibrillatorsHeart stimulatorsCardiac dysfunctionSystole
An extra-systolic stimulation (ESS) therapy addresses cardiac dysfunction including heart failure. ESS therapy employs atrial and / or ventricular extra-systoles via pacing-level stimulation to a heart. These extra-systoles must be timed correctly to achieve beneficial effects on myocardial mechanics (efficacy) while maintaining an extremely low level of risk of arrhythmia induction and excellent ICD-like arrhythmia sensing and detection (security). The present invention relates to therapy delivery guidance and options for improved ESS therapy delivery. These methods may be employed individually or in combinations in an external or implantable ESS therapy delivery device.
Owner:MEDTRONIC INC
Implantable device for evaluating autonomic cardiovascular drive in a patient suffering from chronic cardiac dysfunction
ActiveUS20150073512A1Restore balancePatient outcomeSpinal electrodesCatheterReflexCardiac dysfunction
An implantable device (11) for evaluating autonomic cardiovascular drive in a patient (10) suffering from chronic cardiac dysfunction is provided. A stimulation therapy lead (13) includes helical electrodes (14) configured to conform to an outer diameter of a cervical vagus nerve sheath, and a set of connector pins (28) electrically connected to the helical electrodes (14). A neurostimulator (12) includes an electrical receptacle (25) into which the connector pins (28) are securely and electrically coupled. The neurostimulator (12) also includes a pulse generator configured to therapeutically stimulate the vagus nerve through the helical electrodes (14) in alternating cycles of stimuli application and stimuli inhibition (90) that are tuned to both efferently activate the heart's intrinsic nervous system and afferently activate the patient's central reflexes by triggering bi-directional action potentials. The neurostimulator (12) includes a recordable memory (29) storing a baseline heart rate. The neurostimulator (12) includes an integrated leadless heart rate sensor (31) configured to continually monitor heart rate in light of the baseline heart rate.
Owner:LIVANOVA USA INC
Methods and compositions for treating cardiac dysfunctions
InactiveUS20090022729A1Treating and preventing hypertrophyBiocideDipeptide ingredientsCardiac dysfunctionProphylactic treatment
The present invention provides methods and pharmaceutical compositions for treating or preventing cardiac dysfunctions (e.g., cardiac hypertrophy, cardiac remodeling, or heart failure) in subjects who have or are likely to develop cardiomyopathies. Some of the methods are directed to therapeutic or prophylactic treatment of cardiac dysfunctions in subjects having undergone myocardial injuries such as cardiac ischemia / reperfusion or myocardial infarction. Typically, these methods comprising administering to the subjects a therapeutic composition comprising a compound which can specifically inhibit PAR1 mediated signaling or down-regulate the cellular level of PAR1.
Owner:THE SCRIPPS RES INST +1
Method and system for characterizing cardiovascular systems from single channel data
ActiveUS20150216426A1Cumbersome to executeBroaden applicationMedical simulationElectrocardiographyDiseaseCardiac defects
Methods to identify and risk stratify disease states, cardiac structural defects, functional cardiac deficiencies induced by teratogens and other toxic agents, pathological substrates, conduction delays and defects, and ejection fraction using single channel biological data obtained from the subject. A modified Matching Pursuit (MP) algorithm may be used to find a noiseless model of the data that is sparse and does not assume periodicity of the signal. After the model is derived, various metrics and subspaces are extracted to characterize the cardiac system. In another method, space-time domain is divided into a number of regions (which is largely determined by the signal length), the density of the signal is computed in each region and input to a learning algorithm to associate them to the desired cardiac dysfunction indicator target.
Owner:ANALYTICS FOR LIFE
Heteroarylacrylamides and their use as pharmaceuticals
The present invention relates to heteroarylacrylamides of the formula I,in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
Owner:SANOFI SA
Compositions and methods for treating cardiac dysfunction
InactiveUS20050021089A1Cell receptors/surface-antigens/surface-determinantsVirusesCardiac dysfunctionCardiac pacemaker electrode
Disclosed are methods and systems for restoring cardiac function or preventing cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of the conduction system of the heart. In one embodiment, the invention provides a method of genetically modifying the cells by delivering to the cells one or more coding sequences in a genetic construct capable of modifying the expression of or conductance of ion channels of the cells of the atrioventricular node cells to suppress conductance of impulses therethrough in combination with pacemaker treatment.
Owner:MEDTRONIC INC
Heteroarylacrylamides and their use as pharmaceuticals
The present invention relates to heteroarylacrylamides of the formula I,in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
Owner:SANOFI SA
Pulsation-type auxiliary circulation system, pulsatile flow generation control device, and pulsatile flow generation control method
InactiveUS20080249456A1Enhancing auxiliary circulation effectCoronary artery blood flow is increasedElectrocardiographyOther blood circulation devicesSystoleTreatment effect
Pulsatile flow in synchronization with the systole and diastole of a patient's own pulse is generated during auxiliary circulation therapy administered to a patient under cardiac dysfunction. As a result, the diastole augmentation function is maintained, blood flow to the coronary artery is increased, and the therapeutic effect of intending to restore cardiac function without applying after-loading to the heart is improved.Pulsatile flow generation control device Y incorporated in a pulsation-type auxiliary circulation system (X) as an apparatus system having an electromagnetic valve 7 in blood supply lines (4, 6, 8) on the delivery side of artificial lung 5 and a control means 11 for performing control-output relating to the opening and closing operation of the electromagnetic valve 7. The control means 11 has at least a delay circuit and is such that the electromagnetic valve 7 is actuated to close and is maintained closed for a predetermined time interval based on delay detection and is actuated to open based on delay cancellation so that blood flow is periodically interrupted.
Owner:JOSHO GAKUEN EDUCATIONAL FOUND
Compositions and methods for the treatment and prevention of cardiovascular diseases
InactiveUS20100272711A1Cardiac function was not compromisedDeleterious effectBiocideGenetic material ingredientsCardiac dysfunctionProphylactic treatment
The present invention is directed to a pharmaceutical composition, and methods of use thereof, comprising at least one agent which target multiple adenosine receptors (AR) simultaneously in a stoichiometric relationship (i.e. each AR receptor is targeted to an equal extent). Aspects of the present invention relate to pharmaceutical compositions, and uses thereof, comprising at least one agent which co-activates an A1-adenosine receptor (A1-AR) and an A2A-adenosine receptor (A2A-AR) or a combination of at least one agent which activates an A1-AR and at least one agent which activates an A2A-AR, where both the A1-AR and A2A-AR are activated in a stoichiometric relationship such that the level of biological activation of A1-AR is approximately the same level of biological activation of A2A-AR. Other aspects of the present invention relates to methods for the therapeutic and prophylactic treatment of cardiac dysfunction in a subject having or at risk of having a cardiac dysfunction, for example, but not limited to, for the treatment of a subject with myocardial infarction, such as acute myocardial infarction, coronary ischemia or congestive heart failure and other cardiac dysfunctions.
Owner:THOMAS JEFFERSON UNIV
Tea paste with myocardial ischemia function improving function and preparation method of tea paste
InactiveCN102640829AAnti agingHigh health valueTea substituesCardiovascular disorderCardiac dysfunctionCurative effect
The invention discloses tea paste with a myocardial ischemia function improving function and a preparation method of the tea paste. The tea paste is prepared from the following ingredients in parts by weight: 200 to 350 parts of Puer tea, 300 to 500 parts of fresh burdock, 300 to 500 parts of fresh yam, 50 to 100 parts of Chinese date and 40 to 60 parts of astragalus. The tea paste has the advantages that the extraction process is simple, the extraction efficiency is high, the energy consumption and the loss are little, the cost is low, and the special curative effect can be realized on chronic hypertension, hepatosis and cardiac dysfunction after the tea paste is eaten for a long time.
Owner:LIAOCHENG UNIV
Implantable device for evaluating autonomic cardiovascular drive in a patient suffering from chronic cardiac dysfunction
An implantable device (11) for evaluating autonomic cardiovascular drive in a patient (10) suffering from chronic cardiac dysfunction is provided. A stimulation therapy lead (13) includes helical electrodes (14) configured to conform to an outer diameter of a cervical vagus nerve sheath, and a set of connector pins (28) electrically connected to the helical electrodes (14). A neurostimulator (12) includes an electrical receptacle (25) into which the connector pins (28) are securely and electrically coupled. The neurostimulator (12) also includes a pulse generator configured to therapeutically stimulate the vagus nerve through the helical electrodes (14) in alternating cycles of stimuli application and stimuli inhibition (90) that are tuned to both efferently activate the heart's intrinsic nervous system and afferently activate the patient's central reflexes by triggering bi-directional action potentials. The neurostimulator (12) includes a recordable memory (29) storing a baseline heart rate.
Owner:LIVANOVA USA INC
Treatment of cardiac conditions
InactiveCN102892425APeptide/protein ingredientsPharmaceutical delivery mechanismCardiac dysfunctionDobutamine
The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.
Owner:ZEALAND PHARM AS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com